A BILL 
To provide for an exploration of strategies to increase domes-
tic manufacturing and diversify the supply chain of crit-
ical drugs, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Prescription for Amer-
4
ican Drug Independence Act of 2020’’. 
5
SEC. 2. NATIONAL ACADEMIES STRATEGIES TO INCREASE 
6
DOMESTIC MANUFACTURING OF CRITICAL 
7
DRUGS. 
8
(a) IN GENERAL.—Not later than 14 days after the 
9
date of enactment of this Act, the Secretary of Health and 
10
18:26 May 08, 2020
H6670
2 
•HR 6670 IH
Human Services shall enter into an agreement with the 
1
National Academies of Sciences, Engineering, and Medi-
2
cine (referred to in this section as the ‘‘National Acad-
3
emies’’) under which, not later than 90 days after the date 
4
of entering into the agreement, the National Academies 
5
will— 
6
(1) establish a committee of experts who are 
7
knowledgeable about drug supply issues, including— 
8
(A) sourcing and production of critical 
9
drugs; 
10
(B) sourcing and production of active 
11
pharmaceutical ingredients in critical drugs; 
12
(C) the raw materials and other compo-
13
nents for critical drugs; and 
14
(D) the public health and national security 
15
implications of the current supply chain for 
16
critical drugs; 
17
(2) convene a public symposium to— 
18
(A) analyze the impact of United States 
19
dependence on the foreign manufacturing of 
20
critical drugs on patient access and care, in-
21
cluding in hospitals and intensive care units; 
22
and 
23
(B) recommend strategies to end United 
24
States dependence on foreign manufacturing to 
25
18:26 May 08, 2020
H6670
3 
•HR 6670 IH
ensure the United States has a diverse and vital 
1
supply chain for critical drugs to protect the 
2
Nation from natural or hostile occurrences; and 
3
(3) submit a report on the symposium’s pro-
4
ceedings to the Congress and publish a summary of 
5
such proceedings on the public website of the Na-
6
tional Academies. 
7
(b) SYMPOSIUM.—In carrying out the agreement 
8
under subsection (a), the National Academies shall consult 
9
with— 
10
(1) the Department of Health and Human 
11
Services, the Department of Homeland Security, the 
12
Department of Defense, the Department of Com-
13
merce, the Department of State, the Department of 
14
Veterans Affairs, the Department of Justice, and 
15
any other Federal agencies as appropriate; and 
16
(2) relevant stakeholders, including drug manu-
17
facturers, health care providers, medical professional 
18
societies, State-based societies, public health experts, 
19
State and local public health departments, State 
20
medical boards, patient groups, health care distribu-
21
tors, wholesalers and group purchasing organiza-
22
tions, pharmacists, and other entities with experi-
23
ence in health care and public health, as appro-
24
priate. 
25
18:26 May 08, 2020
H6670
4 
•HR 6670 IH
(c) DEFINITIONS.—For the purposes of this section: 
1
(1) The term ‘‘critical drug’’ means a drug that 
2
is described in subsection (a) of section 506C of the 
3
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
4
356c) (relating to notification of any discontinuance 
5
or interruption in the production of life-saving 
6
drugs). 
7
(2) The term ‘‘drug’’ has the meaning given to 
8
such term in section 201 of the Federal Food, Drug, 
9
and Cosmetic Act (21 U.S.C. 321). 
10
Æ 
18:26 May 08, 2020
H6670
